Trial · NCT02031770
Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
NCT02031770, Not applicable, Completed, University of Colorado, Denver; results first posted 2020-09-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease. Trials, record NCT02031770. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02031770
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
- NCT number
- NCT02031770
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Metabolic Acidosis, Chronic Kidney Disease
- Interventions
- Sodium bicarbonate, Control
- First posted
- 2014-01-09
- Last updated
- 2020-09-22
- Results first posted
- 2020-09-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Brachial Artery Flow Mediated Dilation (FMD) | 6 weeks and 12 weeks | The primary endpoint is change in brachial artery FMD between treatment and control conditions. Each treatment period is 6 weeks in duration with a 2 week washout period in between. Outcome measures will be repeated at the beginning and end of each period. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Brachial Artery Flow Mediated Dilation (FMD) | 6 weeks and 12 weeks | absolute change in percent FMD | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Brachial Artery Flow Mediated Dilation (FMD) | Treatment | 1.1 | Standard Deviation 2.6 | absolute change in percent FMD | |
| Change in Brachial Artery Flow Mediated Dilation (FMD) | Control | -0.7 | Standard Deviation 1.9 | absolute change in percent FMD |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | A: Treatment/Control | 10 | |
| Overall Study | STARTED | B: Control/Treatment | 10 | |
| Overall Study | COMPLETED | A: Treatment/Control | 9 | |
| Overall Study | COMPLETED | B: Control/Treatment | 9 | |
| Overall Study | NOT COMPLETED | A: Treatment/Control | 1 | |
| Overall Study | NOT COMPLETED | B: Control/Treatment | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Treatment | 7 | 20 | 7 |
| other | Nausea | Gastrointestinal disorders | Control | 0 | 20 | 0 |
| other | Leg swelling | Cardiac disorders | Treatment | 4 | 20 | 4 |
| other | Leg swelling | Cardiac disorders | Control | 0 | 20 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Treatment | 11 | 20 |
| Total, other adverse events | Control | 0 | 20 |
| Total, serious adverse events | Treatment | 0 | 20 |
| Total, serious adverse events | Control | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Treatment vs Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02031770
GET https://conductscience.org/api/trials/v1/NCT02031770/registered